Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Lines and Treatments
2.2. Cell Growth Inhibition (MTT Assay)
2.3. Calculating Synergy
2.4. Statistical Analysis for Synergy
2.5. Immunoblotting
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Burris, H.A., III; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997, 15, 2403–2413. [Google Scholar] [CrossRef] [Green Version]
- Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased survival in pancreatic cancer. N. Engl. J. Med. 2013, 369, 1691–1703. [Google Scholar] [CrossRef] [Green Version]
- Herrmann, R.; Bodoky, G.; Ruhstaller, T.; Glimelius, B.; Bajetta, E.; Schüller, J.; Saletti, P.; Bauer, J.; Figer, A.; Pestalozzi, B.; et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 2007, 25, 2212–2217. [Google Scholar] [CrossRef]
- Cunningham, D.; Chau, I.; Stocken, D.D.; Valle, J.W.; Smith, D.; Steward, W.; Harper, P.G.; Dunn, J.; Tudur-Smith, C.; West, J.; et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009, 27, 5513–5518. [Google Scholar] [CrossRef]
- Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancera phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960–1966. [Google Scholar] [CrossRef]
- Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [Google Scholar] [CrossRef] [Green Version]
- Schomburg, L. Selenium, selenoproteins and the thyroid gland: Interactions in health and disease. Nat. Rev. Endocrinol. 2011, 8, 160–171. [Google Scholar] [CrossRef]
- Jenkins, D.; Kitts, D.; Giovannucci, E.L.; Sahye-Pudaruth, S.; Paquette, M.; Blanco Mejia, S.; Patel, D.; Kavanagh, M.; Tsirakis, T.; Kendall, C.; et al. Selenium, antioxidants, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2020, 112, 1642–1652. [Google Scholar] [CrossRef]
- Deng, H.; Liu, H.; Yang, Z.; Bao, M.; Lin, X.; Han, J.; Qu, C. Progress of Selenium Deficiency in the Pathogenesis of Arthropathies and Selenium Supplement for Their Treatment. Biol. Trace Elem. Res. 2021, 1–12. [Google Scholar] [CrossRef]
- Liu, H.; Xu, H.; Huang, K. Selenium in the prevention of atherosclerosis and its underlying mechanisms. Metallomics 2017, 9, 21–37. [Google Scholar] [CrossRef]
- Steinbrenner, H.; Al-Quraishy, S.; Dkhil, M.A.; Wunderlich, F.; Sies, H. Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv. Nutr. 2015, 6, 73–82. [Google Scholar] [CrossRef] [Green Version]
- Solovyev, N.; Drobyshev, E.; Bjørklund, G.; Dubrovskii, Y.; Lysiuk, R.; Rayman, M.P. Selenium, selenoprotein P, and Alzheimer’s disease: Is there a link? Free Radic. Biol. Med. 2018, 127, 124–133. [Google Scholar] [CrossRef]
- Ding, J.; Zhang, Y. Relationship between the Circulating Selenium Level and Stroke: A Meta-Analysis of Observational Studies. J. Am. Coll. Nutr. 2021, 1–9. [Google Scholar] [CrossRef]
- Zhang, J.; Saad, R.; Taylor, E.W.; Rayman, M.P. Selenium and selenoproteins in viral infection with potential relevance to COVID-19. Redox. Biol. 2020, 37, 101715. [Google Scholar] [CrossRef]
- Ip, C.; Dong, Y. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res. 2001, 21, 863–867. [Google Scholar]
- Unni, E.; Koul, D.; Yung, W.K.; Sinha, R. Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res. 2005, 7, R699–R707. [Google Scholar] [CrossRef] [Green Version]
- Das, A.; Bortner, J.; Desai, D.; Amin, S.; El-Bayoumy, K. The selenium analog of the chemopreventive compound S,S’-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer. Chem. Biol. Interact. 2009, 180, 158–164. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Bonorden, M.J.; Li, G.X.; Lee, H.J.; Hu, H.; Zhang, Y.; Liao, J.D.; Cleary, M.P.; Lü, J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev. Res. 2009, 2, 484–495. [Google Scholar] [CrossRef] [Green Version]
- Sinha, I.; Allen, J.E.; Pinto, J.T.; Sinha, R. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Med. 2014, 3, 252–264. [Google Scholar] [CrossRef]
- Vinceti, M.; Filippini, T.; Del Giovane, C.; Dennert, G.; Zwahlen, M.; Brinkman, M.; Zeegers, M.P.; Horneber, M.; D’Amico, R.; Crespi, C.M. Selenium for preventing cancer. Cochrane Database Syst. Rev. 2018, 1, CD005195. [Google Scholar] [CrossRef]
- Alcolea, V.; Karelia, D.N.; Pandey, M.K.; Plano, D.; Singh, P.; Palop, J.A.; Amin, S.; Sanmartín, C.; Sharma, A.K. Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic. Int. J. Mol. Sci. 2019, 20, 521. [Google Scholar] [CrossRef] [Green Version]
- Jablonska, E.; Li, Q.; Reszka, E.; Wieczorek, E.; Tarhonska, K.; Wang, T. Therapeutic Potential of Selenium and Selenium Compounds in Cervical Cancer. Cancer Control. 2021, 28. [Google Scholar] [CrossRef]
- Wang, L.; Wang, J.; Liu, X.; Liu, Q.; Zhang, G.; Liang, L. Association between selenium intake and the risk of pancreatic cancer: A meta-analysis of observational studies. Biosci. Rep. 2016, 36, e00395. [Google Scholar] [CrossRef] [Green Version]
- Lener, M.R.; Scott, R.J.; Wiechowska-Kozłowska, A.; Serrano-Fernández, P.; Baszuk, P.; Jaworska-Bieniek, K.; Sukiennicki, G.; Marciniak, W.; Muszyńska, M.; Kładny, J.; et al. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res. Treat. 2016, 48, 1056–1064. [Google Scholar] [CrossRef] [Green Version]
- Gómez-Tomás, Á.; Pumarega, J.; Alguacil, J.; Amaral, A.; Malats, N.; Pallarès, N.; Gasull, M.; Porta, M.; PANKRAS II Study Group. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Environ. Mol. Mutagen. 2019, 60, 693–703. [Google Scholar] [CrossRef]
- Chatterjee, S.; Combs, G.F., Jr.; Chattopadhyay, A.; Stolzenberg-Solomon, R. Serum selenium and pancreatic cancer: A prospective study in the Prostate, Lung, Colorectal and Ovarian Cancer Trial cohort. Cancer Causes Control. 2019, 30, 457–464. [Google Scholar] [CrossRef]
- Doello, K.; Mesas, C.; Quiñonero, F.; Perazzoli, G.; Cabeza, L.; Prados, J.; Melguizo, C.; Ortiz, R. The antitumor activity of sodium selenite alone and in combination with gemcitabine in pancreatic cancer: An in vitro and in vivo study. Cancers 2021, 13, 3169. [Google Scholar] [CrossRef]
- Karelia, D.N.; Kim, S.K.; Pandey, M.; Plano, D.; Amin, S.; Lu, J.; Sharma, A.K. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. Int. J. Mol. Sci. 2021, 22, 4966. [Google Scholar] [CrossRef]
- Foucquier, J.; Guedj, M. Analysis of drug combinations: Current methodological landscape. Pharmacol. Res. Perspect. 2015, 3, e00149. [Google Scholar] [CrossRef]
- Meyer, C.T.; Wooten, D.J.; Lopez, C.F.; Quaranta, V. Charting the fragmented landscape of drug synergy. Trends Pharmacol. Sci. 2020, 41, 266–280. [Google Scholar] [CrossRef]
- Meyer, C.T.; Wooten, D.J.; Paudel, B.B.; Bauer, J.; Hardeman, K.N.; Westover, D.; Lovly, C.M.; Harris, L.A.; Tyson, D.R.; Quaranta, V. Quantifying drug combination synergy along potency and efficacy axes. Cell Syst. 2019, 8, 97–108.e16. [Google Scholar] [CrossRef] [Green Version]
- Wooten, D.J.; Meyer, C.T.; Lubbock, A.L.R.; Quaranta, V.; Lopez, C.F. MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat. Commun. 2021, 12, 4607. [Google Scholar] [CrossRef]
- Berenbaum, M.C. What is synergy? Pharmacol. Rev. 1989, 41, 93–141. [Google Scholar]
- Wooten, D.J.; Albert, R. Synergy: A Python library for calculating, analyzing and visualizing drug combination synergy. Bioinformatics 2021, 37, 1473–1474. [Google Scholar] [CrossRef]
- Bayat Mokhtari, R.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022–38043. [Google Scholar] [CrossRef] [Green Version]
- Sultana, A.; Ghaneh, P.; Cunningham, D.; Starling, N.; Neoptolemos, J.P.; Smith, C.T. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 2008, 8, 192. [Google Scholar] [CrossRef] [Green Version]
- Djamgoz, M.; Jentzsch, V. Integrative Management of Pancreatic Cancer (PDAC): Emerging Complementary Agents and Modalities. Nutr. Cancer 2021, 1–24. [Google Scholar] [CrossRef]
- Wang, H.; Word, B.R.; Lyn-Cook, B.D. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: The role of human equilibrative nucleoside transporter 1. Anticancer Res. 2011, 31, 3171–3180. [Google Scholar]
- Hagmann, W.; Jesnowski, R.; Löhr, J.M. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010, 12, 740–747. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wooten, D.J.; Sinha, I.; Sinha, R. Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines 2022, 10, 149. https://doi.org/10.3390/biomedicines10010149
Wooten DJ, Sinha I, Sinha R. Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines. 2022; 10(1):149. https://doi.org/10.3390/biomedicines10010149
Chicago/Turabian StyleWooten, David J., Indu Sinha, and Raghu Sinha. 2022. "Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine" Biomedicines 10, no. 1: 149. https://doi.org/10.3390/biomedicines10010149